Gregory P Kaufman, M.D.

Peer-Reviewed Articles

1. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2022. PMID: 35605883.
2. Shank BR, Primeaux B, Yeung EK, Horowitz SB, Lee IY, Roccograndi L, Feng L, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Becnel MR, Thomas SK. Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. Clin Lymphoma Myeloma Leuk 23(4):279-290, 2023. e-Pub 2022. PMID: 36797154.
3. Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional experience. Am J Hematol 97(7):E276-E280, 2022. e-Pub 2022. PMID: 35472167.
4. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
5. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
6. Dike PN, Pereira MM, Kaufman GP, Patel K, Schady D, Vogel AM, van Buren KL, Fishman DS. A Rare Case of Pediatric Amyloidosis Presenting as Upper Gastrointestinal Bleeding. J Pediatr Gastroenterol Nutr 74(3):e73, 2022. e-Pub 2021. PMID: 34560726.
7. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):1-12, 2022. e-Pub 2021. PMID: 34686083.
8. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
9. Handley G, Khawaja F, Kondapi DS, Lee HJ, Kaufman GP, Neelapu SS, Fayad LE, Tummala S, Chi L, Strati P, Mulanovich VE. Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy. Int J Infect Dis 112:327-329, 2021. e-Pub 2021. PMID: 34600133.
10. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
11. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192(4):e115-e120, 2021. e-Pub 2021. PMID: 33486754.
12. Agha AM, Palaskas N, Patel AR, DeCara J, Parwani P, Iliescu C, Durand JB, Kim P, Hassan S, Gladish G, Lee HC, Kaufman GP, Lopez-Mattei JC. Cardiac Magnetic Resonance Predicting Outcomes among Patients at Risk for Cardiac AL Amyloidosis. Front Cardiovasc Med 8:626414, 2021. e-Pub 2021. PMID: 34268341.
13. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
14. Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Organ Responses with Daratumumab Therapy in Previously Treated AL Amyloidosis. Blood Adv 4(3):458-466, 2020. PMID: 32027745.
15. Kaufman GP, Cerchione C. Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. Front Oncol 10:624573, 2020. e-Pub 2021. PMID: 33614504.
16. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol 145(6):1527-1557, 2019. e-Pub 2019. PMID: 31028541.
17. Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, O'Shaughnessy M, Liedtke M. Grading cardiac response in AL amyloidosis: implications for relapse and survival. Br J Haematol. e-Pub 2018. PMID: 30569572.
18. Dinner S, Dunn TJ, Price E, Coutré SE, Gotlib J, Berube C, Kaufman GP , Medeiros BC, Liedtke M. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol 108(3):267-273, 2018. PMID: 29802551.
19. Kaufman GP , Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood 130(7):900-902, 2017. PMID: 28615223.
20. Gu JJ, Kaufman GP , Mavis C, Czuczman MS, Hernandez-Ilizaliturri FJ. Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells. Oncotarget 8(8):12741-12753, 2016. PMID: 28055975.
21. Kaufman GP , Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia 30(3):633-639, 2016. PMID: 26487275.
22. Kaufman GP , Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90(3):181-186, 2015. PMID: 25388651.
23. Kaufman GP , Ristow KM, Markovic SN, Porrata LF. The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use. Blood and Lymphatic Cancer: Targets and Therapy(4):39-44, 2014.
24. Kaufman GP , Aksamit AJ, Klein CJ, Yi ES, Delone DR, Litzow MR. Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT). Eur J Haematol 92(1):83-7, 2014. PMID: 24118404.
25. Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP , Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol 162(5):657-69, 2013. PMID: 23826755.

Invited Articles

1. Kaufman GP, Liedtke ML. Ask the Hematologists: Management Approach to Patients with Newly Diagnosed Cardiac Immunoglobulin Light-Chain Amyloidosis. The Hematologist – American Society of Hematology (ASH) News and Reports 13(May-June):3, 2016.

Abstracts

1. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE and Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 136(1453), 2020.
2. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, MD, and Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. Blood 136(1453), 2020.
3. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 136(2423), 2020.
4. Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(1512), 2020.
5. Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, and Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 136(2419), 2020.
6. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, and Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 136(1394), 2020.
7. Yeung EK, Primeaux BR, Horowitz SB, Shank BR, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, and Thomas SK. Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM). Blood 136(3216), 2020.
8. Becnel MR, Horowitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, and Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. Blood 136(1371), 2020.
9. Gunther JR, Dabaja B, Fang P, Anakwenze CP, Manasanch EE, Lee H, Patel K, Kaufman G, Thomas S, Orlowski R, Weber D, Wang XA, Amini B, Lin P, Pinnix CC. Management and Long-Term Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 2020.
10. Shank BR, Primeaux B, Horowitz SB, Yeung EK, Lee IY, Kaufman GP, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Weber DM, Thomas SK. Daratumumab and hyperfractionated cyclophosphamide HyperCy/Dex with and without carfilzomib for the treatment of relapsed/refractory multiple myeloma. ASCO 2020 abstracts 38(15_suppl):e20528-e20528, 2020.
11. Dike P, Pereira M, Hicks J, Kaufman G, Vogel A, Patel K. A rare case of gastric amyloidosis in a pediatric patient presenting with an upper gastrointestinal bleed. 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, 2020.
12. Chung A, Kaufman GP, Sidana S, Iberri S, Eckhert E, Schrier S, Lafayette R, Arai S, Witteles R, Liedtke M. Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses. Blood, 2019.
13. Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, Thomas SK, Iyer S, Mailankody S, Korde N, Amini B, Lin P, Berkova Z, Weber DM, Lei F, Lendvai N, Hildebrandt M, Neelapu SS, Orlowski RZ, Landgren O. A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). Blood, 2019.
14. Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier S, Arai S, Lafayette R, Witteles R, Liedtke M. Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis. Blood, 2019.
15. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta RS, Kaufman GP, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Retrospective Analysis. Blood, 2019.
16. Eckhert EK, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, O'Shaughnessy M, Liedtke M. Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis. Blood 132(Suppl 1):4486-4486, 2018.
17. Kaufman GP, Schrier S, Witteles R, Ulloa P, Lugtu M, Arai S, O’Shaughnessy M, Lafayette R, Liedtke M. Early Light Chain Kinetics and Depth/Duration of Hematologic Responses to Daratumumab in Previously Treated Light Chain Amyloidosis. EHA 2018, 2018.
18. Kaufman GP, Witteles R, Wheler M, Ulloa P, Lugtu M, Arai S, Schrier S, Lafayette R, Liedtke M.. Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. Blood, 2016.
19. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, Kumar S.. Outcomes of high, t(11;14), and standard cytogenetic risk multiple myeloma following early high dose therapy and autologous hematopoietic cell transplantation (SCT). ASCO 2015, 2015.
20. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Rajkumar SV, Kumar S.. Adverse cytogenetics, with or without trisomies in patients undergoing high dose therapy for multiple myeloma and impact of post-transplant maintenance therapy. Blood, 2014.
21. Gu J, Hernandez-Ilizaliturri F, Kaufman GP , Mavis C, Czuczman MS. Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL). Blood 120(21), 2012.
22. Gu J, Hernandez-Ilizaliturri F, Kaufman GP , Mavis C, Czuczman MS. Bortezomib (BTZ) Inhibits p21-Dependent Senescence and Triggers Mitotic Catastrophe in Rituximab-Chemotherapy Resistant Cell Lines (RRCL). Blood 120(21), 2012.
23. Gu J, Czuczman NM, Kaufman GP , Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. The novel proteasome inhibitor carfilzomib (CFZ) potentiates the anti-tumor activity of chemotherapeutic agents in rituximab-chemotherapy resistant lymphoma through inducing G2/M cell cycle arrest and cell death. Blood 118(21):4970, 2011.
24. Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, Mavis C, Czuczman MS.. Carfilzomib (CFZ): a novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agents. Blood 116(21):4908, 2010.
25. Kaufman GP, Hernandez-Ilizaliturri FJ, Mavis C, Patil R, Czuczman MS. Evaluation of carfilzomib to disrupt the apoptotic threshold of B-cell lympho-mas by targeting Bcl-2 family members and overcome rituximab (R) chemotherapy resistance. J Clin Oncol 28(15_suppl), 2010.